Dr E Ann Yeh - Longer-term safety of B-cell therapies in MS

Поделиться
HTML-код
  • Опубликовано: 24 ноя 2024

Комментарии • 4

  • @demoskunk
    @demoskunk Год назад +4

    Very interesting. Since Ocrevus is the only dmt currently available for PPMS, I'll have to continue taking my chances with it.
    Hopefully the BTK inhibitors get FDA approval soon.

  • @ernietollar407
    @ernietollar407 Год назад +1

    Ocrevus didn't help my PPMS so I'm in Mexico for HSCT in 5 days (a treatment which is effective in rebooting the faulty immune system of many with MS with cyclophosphide. Rituxan is used after the chemo.)